Biovica International (BIOVIC-B.ST) Stock Analysis & AI Equity Report
Biovica International (BIOVIC-B.ST) overview
Biovica International (BIOVIC-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Biovica International reported revenue of SEK 13.4m and operating profit of SEK -70.0m; the year-end share price was 0.35 SEK and market capitalisation was SEK 82.2m. Biovica International is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Biovica International's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Biovica International
Biovica International develops and commercializes blood-based biomarker assays for cancer treatment monitoring. Its main product is DiviTum TKa, a test that measures cell proliferation and is used to assess therapy effectiveness, initially in metastatic breast cancer. The company also collaborates with cancer institutes and pharmaceutical companies on clinical development.
Generate the Biovica International report
Biovica International is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Biovica International and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Biovica International
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.